Search - tctmd.com

Displaying 301 - 320 of 630

Sort: Relevancy | Date

Presentation TVT 2019

Advanced Design Features and Future Vision

Presenter: Jeffrey Popma

June 13, 2019

Presentation TVT 2019

Impact of Initial Evolut TAVR Deployment Orientation on Final Valve Orientation and Coronary Reaccess: A Pilot Study

Presenter: Gilbert Tang

June 13, 2019

News Conference News EuroPCR 2019

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Michael O'Riordan

May 29, 2019

CHOICE: Better Hemodynamics, Less Structural Deterioration with CoreValve

News Conference News EuroPCR 2019

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Michael O'Riordan

May 24, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Conference News EuroPCR 2019

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

Michael O'Riordan

May 22, 2019

News Conference News HRS 2019

HRS Urges Members to Get Aboard the Digital Health Train

Todd Neale

May 10, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Latest Observational Data Support TAVR Durability Through 7 Years

Caitlin E. Cox

April 12, 2019

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Daily News

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

L.A. McKeown

March 29, 2019

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News CRT 2019

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Yael L. Maxwell

March 04, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

News Daily News

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

Shelley Wood

February 19, 2019

Manuscript

The Evolution of the Program Coordinator: From One Valve to the Whole Heart

January 07, 2019

Advertisement

Advanced Design Features and Future Vision

Impact of Initial Evolut TAVR Deployment Orientation on Final Valve Orientation and Coronary Reaccess: A Pilot Study

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

HRS Urges Members to Get Aboard the Digital Health Train

FDA Approves Lotus Edge, Ushering Third Device Into US Market

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Latest Observational Data Support TAVR Durability Through 7 Years

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

The Evolution of the Program Coordinator: From One Valve to the Whole Heart

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content